Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Revvity Inc

PKN:MUN

Revvity Inc

Actions
  • Price (EUR)108.95
  • Today's Change1.95 / 1.82%
  • Shares traded50.00
  • 1 Year change+34.11%
  • Beta--
Data delayed at least 15 minutes, as of Nov 26 2024 07:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.

  • Revenue in USD (TTM)2.72bn
  • Net income in USD258.26m
  • Incorporated1947
  • Employees11.50k
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.